Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids
Stopped: Study was not started due to COVID-19 pandemic.
United States0Started 2020-01-24
Plain-language summary
This study evaluates laparoscopic-guided TAP block for reducing opioid use after minimally invasive foregut and bariatric surgeries, comparing Bupivacaine HCL with Exparel®. Secondary outcomes include pain scores, length of stay, and PONV medication use.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* gastric bypass \& sleeve gastrectomy, duodenal switch and minimally invasive elective anti-reflux foregut surgeries such as - hiatal hernia repair, fundoplication and Heller myotomy.
Exclusion Criteria:
* Subjects who are known to be
* Allergic to Bupivacaine
* Chronic opioid users Page 4
* Had/have neurological conditions
* Have a diagnosis of chronic pain syndrome which requires them to consume regular analgesics \> 3-months
* American Society of Anesthesiologists (ASA) Class IV \& V patients with severe systemic disease that is a constant threat to life.
* Patients with abdominal drain use
* Patients with significant cardiovascular, liver or renal disease
* Presence of contraindications for bariatric or foregut surgery.
* Patients presenting postoperative complications will be excluded from final analysis \& final data set
* History of bariatric or foregut surgery
* Patients who are pregnant
* Patients who are under the age of 18